HK Stock Market Move | SKB BIO-B(06990) rose more than 3%. SKB535 and SKB571's new drug clinical trial applications have been approved by the National Drug Administration.

SKB BIO-B (06990) rose more than 3%, as of the time of writing, it rose by 2.86% to 158.4 Hong Kong dollars, with a turnover of 13.2731 million Hong Kong dollars. On the news front, SKB BIO-B announced that on November 15, 2024, the company received a clinical trial notification letter for the innovative drug SKB535 developed by the company from the National Medical Products Administration (NMPA) Drug Evaluation Center. According to the NMPA official website, SKB535 is the first optimized innovative drug clinical trial review and approval pilot project approved by the NMPA, with a review and approval time of 21 days. SKB535 is a new ADC drug developed by the company using the OptiDCTM platform technology based on the biological characteristics of the target, with independent intellectual property rights, showing good efficacy and safety in preclinical studies, and intended for the treatment of advanced solid tumors. On the same day, SKB BIO-B announced that on November 15, 2024, the company received a clinical trial notification letter for the new drug SKB571 developed by the company from the National Medical Products Administration Drug Evaluation Center. SKB571 is a new dual-antibody ADC targeting a variety of solid tumors such as lung cancer and gastrointestinal tumors. In the third quarter of 2024, the company was informed by MSD (Merck & Co., Inc., based in Kenilworth, New Jersey, USA) regarding the exercise of the exclusive selection rights for SKB571.